(Albany, USA) DelveInsight’s “Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
Some of the key facts of the Pemphigus Vulgaris Market Report:
- The Pemphigus Vulgaris market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- The United States Pemphigus Vulgaris Market accounted for approximately USD 250 million in 2023.
- In August 2024, Treatment has begun for the first patient in an investigator-initiated basket trial (IIT) evaluating AlloNK® in combination with rituximab for conditions including rheumatoid arthritis, pemphigus vulgaris, granulomatosis with polyangiitis/microscopic polyangiitis, and systemic lupus erythematosus (SLE). This trial is being conducted by Integral Rheumatology & Immunology Specialists (IRIS), a community rheumatology clinic, highlighting the potential to provide AlloNK® to patients in community settings as well as in academic and transplant centers. The study aims to assess the safety, tolerability, and clinical efficacy of AlloNK® (also referred to as AB-101).
- Among the 7MM, the United States accounted for the highest number of cases of Pemphigus Vulgaris in 2023, with nearly 40,000 cases. These cases are anticipated to increase by 2034.
- The projections indicate the highest diagnosed prevalence of Pemphigus Vulgaris in the United States, with an estimated around 14,000 cases in the year 2022.
- Among the entire diagnosed population of nearly 14,000 Pemphigus Vulgaris cases in the United States, the highest incidence was identified in the age group of 60–69 years, while the lowest cases were observed in the 0–17 years age group in the year 2022.
- Pemphigus Vulgaris projections indicate that within the entire diagnosed prevalent population of Pemphigus Vulgaris in the US in 2022, around 6,000 cases were categorized as mild, 4,000 as moderate, and 4,300 accounted for severe cases.
- Within the EU4 and the UK, Germany reported the highest diagnosed prevalent population of Pemphigus Vulgaris, totaling around 8,000 cases, followed by the United Kingdom. In contrast, France had the lowest diagnosed prevalent population, with approximately 3,000 cases in 2022.
- Key Pemphigus Vulgaris Companies: Roche, Cabaletta Bio, Principia Biopharma, Genentech, Inc., Kemia, Inc, argenx Rho Federal Systems Division, Inc, and others
- Key Pemphigus Vulgaris Therapies: PRN1008, Mycophenolate Mofetil, KC706, efgartigimod PH20 SC, Moderna mRNA-1273, and others
- The Pemphigus Vulgaris epidemiology based on gender analyzed that a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries during the study period (2020–2034)
- The Pemphigus Vulgaris market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pemphigus Vulgaris pipeline products will significantly revolutionize the Pemphigus Vulgaris market dynamics.
Pemphigus Vulgaris Overview
Pemphigus Vulgaris is a rare autoimmune disorder characterized by the formation of painful, fluid-filled blisters and sores on the skin and mucous membranes. It is caused by the immune system mistakenly producing antibodies that attack healthy cells, specifically the cells of the skin and mucous membranes.
Get a Free sample for the Pemphigus Vulgaris Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/pemphigus-vulgaris-market
Pemphigus Vulgaris Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Pemphigus Vulgaris Epidemiology Segmentation:
The Pemphigus Vulgaris market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Prevalence of Pemphigus Vulgaris
- Prevalent Cases of Pemphigus Vulgaris by severity
- Gender-specific Prevalence of Pemphigus Vulgaris
- Diagnosed Cases of Episodic and Chronic Pemphigus Vulgaris
Download the report to understand which factors are driving Pemphigus Vulgaris epidemiology trends @ Pemphigus Vulgaris Epidemiology Forecast
Pemphigus Vulgaris Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pemphigus Vulgaris market or expected to get launched during the study period. The analysis covers Pemphigus Vulgaris market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pemphigus Vulgaris Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Pemphigus Vulgaris Therapies and Key Companies
- PRN1008: Principia Biopharma
- Mycophenolate Mofetil: Genentech, Inc.
- KC706: Kemia, Inc
- efgartigimod PH20 SC: argenx
- Moderna mRNA-1273: Rho Federal Systems Division, Inc
Discover more about therapies set to grab major Pemphigus Vulgaris market share @ Pemphigus Vulgaris Treatment Landscape
Scope of the Pemphigus Vulgaris Market Report
- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Pemphigus Vulgaris Companies: Roche, Cabaletta Bio, Principia Biopharma, Genentech, Inc., Kemia, Inc, argenx Rho Federal Systems Division, Inc, and others
- Key Pemphigus Vulgaris Therapies: PRN1008, Mycophenolate Mofetil, KC706, efgartigimod PH20 SC, Moderna mRNA-1273, and others
- Pemphigus Vulgaris Therapeutic Assessment: Pemphigus Vulgaris current marketed and Pemphigus Vulgaris emerging therapies
- Pemphigus Vulgaris Market Dynamics: Pemphigus Vulgaris market drivers and Pemphigus Vulgaris market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Pemphigus Vulgaris Unmet Needs, KOL’s views, Analyst’s views, Pemphigus Vulgaris Market Access and Reimbursement
To know more about Pemphigus Vulgaris companies working in the treatment market, visit @ Pemphigus Vulgaris Clinical Trials and Therapeutic Assessment
Table of Contents
1. Pemphigus Vulgaris Market Report Introduction
2. Executive Summary for Pemphigus Vulgaris
3. SWOT analysis of Pemphigus Vulgaris
4. Pemphigus Vulgaris Patient Share (%) Overview at a Glance
5. Pemphigus Vulgaris Market Overview at a Glance
6. Pemphigus Vulgaris Disease Background and Overview
7. Pemphigus Vulgaris Epidemiology and Patient Population
8. Country-Specific Patient Population of Pemphigus Vulgaris
9. Pemphigus Vulgaris Current Treatment and Medical Practices
10. Pemphigus Vulgaris Unmet Needs
11. Pemphigus Vulgaris Emerging Therapies
12. Pemphigus Vulgaris Market Outlook
13. Country-Wise Pemphigus Vulgaris Market Analysis (2020–2034)
14. Pemphigus Vulgaris Market Access and Reimbursement of Therapies
15. Pemphigus Vulgaris Market Drivers
16. Pemphigus Vulgaris Market Barriers
17. Pemphigus Vulgaris Appendix
18. Pemphigus Vulgaris Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/regulatory-analysis-services